New drug trial targets rare nasal cancer
NCT ID NCT07527169
First seen Jun 27, 2026 · Last updated Aug 13, 2026 · Updated 2 times
Summary
This phase 2 study tests the drug zanzalintinib in 16 adults with recurrent or metastatic olfactory neuroblastoma, a rare cancer of the nasal cavity. The goal is to see if the drug can help control the disease and to check its safety. Participants must not have had prior treatment with similar drugs.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- zanzalintinib (a drug taken orally that targets blood vessel growth in tumors)
- What this could lead to
- If it works, this could offer a new treatment option to control recurrent or metastatic olfactory neuroblastoma, a rare cancer.
- What could go wrong
- This is a small, early-phase trial with only 16 participants, so results may not apply broadly. The drug may cause side effects or fail to control the cancer.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC OLFACTORY NEUROBLASTOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
UT MD Anderson
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.